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Abstract
Approximately 20% of patients with bladder cancer are diagnosed with muscle- invasive 
disease (MIBC). The treatment involves radical cystectomy, but almost 50% of patients 
with MIBC eventually relapse and develop metastasis. The use of platinum- based 
chemotherapy in the neoadjuvant setting or for metastatic patients has been shown to 
improve the overall survival in a subset of patients. Unfortunately, no biomarkers are 
available to select patients with MIBC who will benefit from chemotherapy or to moni-
tor the efficacy of the treatment. Recently, long noncoding RNAs (lncRNAs) were 
shown to regulate a variety of processes involved in the development and progression 
of cancer, including bladder cancer. Moreover, several lncRNAs have been shown to 
play a role in chemotherapy resistance. Here, we analyzed lncRNA expression associ-
ated with response to platinum- based chemotherapy in metastatic MIBC using data 
from the MiTranscriptome lncRNA expression database. Expression of the lncRNA, 
LINC00857, was found to be upregulated in tumors from patients that did not respond 
to platinum- based chemotherapy. Moreover, high expression of LINC00857 is corre-
lated with shorter recurrence- free and overall survival of patients with MIBC. 
Knockdown of LINC00857 significantly decreased cell viability of bladder cancer cell 
lines through the induction of apoptosis. Furthermore, LINC00857 knockdown sensi-
tized UM- UC- 3 and T24 bladder cancer cells to cisplatin, via the negative regulation of 
the LMAN1 gene. Our data indicate that LINC00857 plays an important role in the regu-
lation of response to platinum- based chemotherapy. LINC00857 potentially could serve 
as a novel prognostic and predictive biomarker and might be a therapeutic target to 
overcome cisplatin resistance in patients with MIBC.
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1 |  INTRODUCTION
Urinary bladder cancer ranks as the ninth most common 
cancer, with approximately 430 000 new cases and 165 000 
deaths every year worldwide.1 About 20% of the patients 
are diagnosed with muscle- invasive bladder cancer (MIBC), 
which invades through the lamina propria into the muscle 
layer (stage T2), perivesical tissue (stage T3), or adjacent 
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organs (stage T4).2 Radical cystectomy is the gold standard 
treatment for MIBC. However, almost 50% of patients with 
MIBC relapse and develop local or distant metastasis, and 
the 5- year recurrence- free survival is approximately 74% for 
patients with T2 tumors, 52% for T3 tumors, and 36% for T4 
tumors. The use of neoadjuvant cisplatin- based chemother-
apy (NAC) has been shown to improve the overall survival 
(OS) by 5%- 8%. The treatment of metastatic MIBC also in-
volves cisplatin- based chemotherapy. Unfortunately, roughly 
half of the patients that are treated with cisplatin- based che-
motherapy show a treatment response. These patients have a 
prolonged survival up to 14 months.3,4
The selection of patients with MIBC who will benefit 
from chemotherapy represents a major challenge in clini-
cal practice. Multiple studies have evaluated prognostic and 
predictive biomarkers in MIBC.5,6 For example, somatic al-
terations in DNA damage response and DNA repair (DDR) 
genes have been associated with improved response to 
platinum- based chemotherapy in advanced MIBC.7 Also, 
the prognostic and predictive value of p53 alterations has 
been widely investigated, but neither a prognostic value of 
p53 nor a benefit of methotrexate, vinblastine, doxorubicin, 
and cisplatin (MVAC) chemotherapy in patients with p53- 
positive tumors was found.8 Changes in circulating tumor 
cells (CTCs) were shown to correlate with the clinical out-
come of metastatic patients with bladder cancer after MVAC 
chemotherapy, as CTC- positive patients showed significantly 
shorter progression- free and overall survival.9 Recently, sev-
eral groups have identified molecular subtypes of bladder 
cancer, and these were found to influence the response to 
NAC. The basal subtype of MIBC showed the highest bene-
fit in OS in comparison with the luminal, luminal- infiltrated, 
and claudin- low subtypes.10 Until now, however, there is not 
enough evidence supporting clinical use of these biomark-
ers.3,4 Therefore, conformation of these studies or discovery 
of new biomarkers for MIBC is needed to identify responders 
to chemotherapy, monitor the treatment, and predict patient 
outcome.
Long noncoding RNAs (lncRNAs) are non- protein- 
coding transcripts of at least 200 nucleotides that are ex-
pressed by RNA polymerase II activity and that undergo 
splicing and polyadenylation. LncRNAs outnumber the 
protein- coding genes, and their expression is often lineage- 
specific and in malignancies even cancer- specific.11 Many 
lncRNAs are able to modify gene expression at differ-
ent levels, depending on their cellular localization, ei-
ther through interactions with chromatin modifiers and 
regulation of transcription in cis or trans or through the 
regulation of mRNA stability and protein translation.12 
LncRNAs were found to be involved in the regulation of 
all different hallmarks of cancer including cell prolifera-
tion, cell viability, growth suppression, cell motility, and 
angiogenesis.
Several lncRNAs were shown to modify chemotherapy 
response in bladder cancer. For example, UCA1 expression 
levels were found to be increased upon cisplatin treatment, 
and through activation of Wnt signaling, UCA1 contributed 
to chemoresistance.13 UCA1 was also shown to activate the 
CREB transcription factor and miR-196a-5p, the latter mod-
ulating apoptosis induced by combined gemcitabine and 
cisplatin (Gem/Cis) treatment.14 Additionally, GAS515 and 
HOTAIR16 were found to be prognostic biomarkers. GAS5 
and HOTAIR expression levels were found to be deregu-
lated in bladder cancer, and their expression was shown to 
be associated with tumor grade and disease- free survival.15,16 
Moreover, modulation of GAS5 and HOTAIR expression lev-
els was found to affect proliferation of bladder cancer cells 
and to sensitize them to doxorubicin.15,16
Biomarkers for the accurate selection of patients with 
MIBC who may benefit from platinum- based chemotherapy 
are lacking. LncRNAs regulate a variety of cellular processes 
involved in cell survival and chemoresistance, and their ex-
pression has been shown to be deregulated in bladder cancer. 
Therefore, we analyzed expression levels of lncRNAs using 
the MiTranscriptome lncRNA expression database11 to iden-
tify new noncoding biomarkers that are associated with the 
response to platinum- based chemotherapy in MIBC. The ef-
fect of the identified lncRNA, LINC00857, on cisplatin sensi-
tivity was further characterized in vitro using loss of function 
studies in bladder cancer cells.
2 |  MATERIALS AND METHODS
2.1 | Identification of lncRNAs associated 
with platinum- based chemotherapy response
LncRNAs expression data for MIBC and normal urothelium 
were downloaded from the MiTranscriptome database (http://
mitranscriptome.org).11 Protein- coding gene expression data 
and clinical data (including response to chemotherapy) were 
downloaded from FIREHOSE Broad GDAC (Broad Institute 
TCGA Genome Data Analysis Center (2016): Firehose 2016 
01 28 run. Broad Institute of MIT and Harvard. https://doi.
org/10.7908/c11g0km9). Patients’ characteristics are listed 
in Table S1. Filtering of the data was performed as described 
previously,17 and lncRNAs associated with chemotherapy re-
sponse were selected from the 12 037 lncRNAs (unpaired t 
test).
2.2 | Association between gene 
expression and survival
The association between LINC00857 and LINC00857 tar-
get gene expression levels and overall survival (OS) of 
MIBC was analyzed using the Oncolnc portal (http://www.
oncolnc.org). Recurrence- free survival (RFS) data were 
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downloaded from cBioPortal.18,19 Kaplan- Meier curves 
were compared using a log- rank test (GraphPad Prism), 
and Cox proportional hazard regression analysis was 
performed.
2.3 | Cell culture
UM- UC- 3 (ATCC: CRL- 1749) and T24 (ATCC: HTB- 4) 
bladder cancer cell lines were maintained in RPMI- 1640 me-
dium (Invitrogen) supplemented with 10% fetal calf serum 
(Sigma- Aldrich, F7524) and L- glutamine and cultured in at 
37°C and 5% CO2. Cell lines were authenticated using the 
PowerPlex 21 PCR kit (Promega) by Eurofins Genomics, and 
all cell cultures were mycoplasma- free.
2.4 | siRNA- mediated knockdown of 
LINC00857 and gene expression
Silencer Select small interfering RNAs (siRNAs) directed 
against LINC00857,20 LMAN1, PPP2R5E, and a Silencer 
Select negative control No.1 siRNA were used (Ambion/
Thermo Fisher Scientific; Table S2). T24 and UM- UC- 3 
bladder cancer cell lines were transfected with siRNAs at a 
20 nM final concentration using Lipofectamine RNAiMAX 
transfection reagent (Thermo Fisher Scientific), according to 
the manufacturer’s instructions.
2.5 | RNA isolation and RT- qPCR
Total RNA was isolated using TRIzol reagent (Invitrogen), 
according to manufacturer’s instructions. RNA was first 
treated with DNase I (Invitrogen), and then random- primed 
cDNA was synthesized using SuperScript II reverse tran-
scriptase (Invitrogen). Gene expression levels were deter-
mined by SYBR Green qPCR (Roche) using a LightCycler 
LC480 instrument (Roche). Relative gene expression levels 
were calculated using the ΔΔCt method using the HP1BP3 
and GAPDH genes for normalization. Primer sequences are 
listed in Table S2.
2.6 | Cell viability assay
Cell viability was evaluated at regular time points after trans-
fection (48 hours) using the CellTiter- Glo luminescence 
assay (Promega), according to the manufacturer’s instruc-
tions. Luminescence was measured on a Victor3 multilabel 
reader (Perkin Elmer). All experiments were performed in 
triplicate.
2.7 | Colony formation assay
One day after transfection, cells were seeded in 6- well 
plates at low density and cultured at standard conditions for 
2 weeks. Colonies were fixed with 3% paraformaldehyde and 
stained with 0.01% crystal violet (Merck). The colonies were 
analyzed using ImageJ software. All experiments were per-
formed in triplicate.
2.8 | Apoptosis assay
Two days after transfection, caspase- 3/7 activity was meas-
ured using the Apo- ONE Homogeneous Caspase- 3/7 Assay 
(Promega), according to the manufacturer’s instructions. The 
luminescence signals were measured on a Victor3 multilabel 
reader (Perkin Elmer) and normalized to the input, that is, 
cell numbers (assessed by CellTiter- Glo assay). All experi-
ments were performed in triplicate.
2.9 | Cisplatin sensitivity assay
Two days after transfection cells were treated with increas-
ing doses of cisplatin (Sigma). Cell viability was assessed 
using 3- (4,5- dimethylthiazol- 2- yl)- 2,5- diphenyl- 2H- tetrazo
lium bromide (MTT) assay 24 and 48 hours after cisplatin 
treatment. After 4 hours of incubation, the medium contain-
ing MTT reagent was removed and DMSO (Sigma) was 
added. The optical density (OD) was measured at 595 nm on 
an iMark microplate reader (Bio- Rad). The data were com-
pared to nontreated cells. All experiments were performed in 
triplicate.
3 |  RESULTS
3.1 | Identification of lncRNAs associated 
with platinum- based chemotherapy response 
and MIBC progression
To identify long noncoding RNAs that are associated with 
chemotherapy response, we analyzed lncRNA expression 
levels in patients with MIBC who received cisplatin- based 
chemotherapy after cystectomy. LncRNA expression data in 
MIBC were derived from the MiTranscriptome dataset de-
scribed by Iyer et al11. We identified 154 and 225 lncRNAs 
that are significantly associated with the response to Gem/
Cis or platinum only treatment, respectively (Table S3). 
Previously, LINC00857 was identified as one of the most 
upregulated lncRNAs in lung cancer, and high LINC00857 
expression was associated with shorter overall survival of 
patients with lung cancer.20 Therefore, we decided to fur-
ther focus on LINC00857. LINC00857 expression was found 
to be increased in MIBC in patients that did not respond to 
Gem/Cis (P = .032) nor to platinum- based chemotherapy 
(P = .011; Figure 1A).
Although LINC00857 was not significantly upregulated in 
MIBC in comparison with normal urothelium (Figure 1B), sig-
nificant differences in recurrence- free (RFS, P = .021; Figure 
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S1A) and overall survival (OS, P = .047; Figure S1B) were 
observed when patients were divided into 2 subgroups based 
on median LINC00857 expression. As high LINC00857 ex-
pression was associated with chemotherapy resistance, patients 
with MIBC were further divided into 2 groups: patients with 
high (>75th percentile) and patients with low (<75th percen-
tile) LINC00857 expression. Patients with MIBC with high 
LINC00857 expression were found to have significantly shorter 
RFS (P = .029; Figure 1C) with median 12.2 months in com-
parison with 25.2 months for patients with lower LINC00857 
expression. LINC00857 expression was found also to be asso-
ciated with significant decrease in median OS, decreasing from 
26.9 months in the low expression group to 18 months in the 
high expression group (P = .006; Figure 1D). Moreover, high 
LINC0085 expression was found to be associated with positive 
lymph nodes at the time of diagnosis and with more frequent 
progression after cystectomy (P = .003 and P = .019, resp.; 
Table S4). In multivariate analysis, LINC00857 expression re-
mained an independent predictor of OS (P = .025, Table S5) 
but not RFS (P = .317, Table S6).
3.2 | LINC00857 knockdown decreases 
survival of bladder cancer cells
To investigate the role of LINC00857 in bladder cancer, an 
siRNA20 was used to knock down its expression in 2 muscle- 
invasive bladder cancer- derived cell lines, T24 and UM- UC- 3 
(Figure 2A). Reduced expression of LINC00857 significantly 
reduced the viability of T24 cells (P = .003; Figure 2B), al-
though no increase in caspase 3/7 activity was observed 
(P = .618; Figure 2C). The decrease in cell viability of UM- 
UC- 3 cells (P = .130; Figure 2B), was accompanied by a 
firm induction of apoptosis, marked by high caspase 3/7 ac-
tivity (P = .027; Figure 2C). Colony- forming assays showed 
that LINC00857 knockdown impaired growth of cancer cells 
marked by a reduction in the number of colonies formed by T24 
and UM- UC- 3 cells (P = .01 and P = .005, resp.; Figure 2D).
3.3 | Knockdown of LINC00857 sensitizes 
bladder cancer cells to cisplatin
LINC00857 upregulation was found to be associated with de-
creased platinum- based chemotherapy response. Therefore, 
we evaluated whether knockdown of LINC00857 could sensi-
tize T24 and UM- UC- 3 bladder cancer cells to cisplatin. Using 
LINC00857- specific siRNAs, lncRNA levels were reduced 
more than 90%, compared to negative control transfected cells 
(Figure 3A). LINC00857 knockdown sensitized both T24 and 
UM- UC- 3 cells to cisplatin (Figures 3B,C). The dose of cispl-
atin needed to reduce cell viability by 50% (IC50 value) is more 
than 2- fold lower in cells with knockdown of LINC00857 com-
pared to control cells. Interestingly, knockdown of LINC00857 
led to increased cisplatin sensitivity of UM- UC- 3 cells in a wide 
range of cisplatin concentrations (Figure 3B). In contrast, the 
sensitivity of T24 cell line was found to be increased only in a 
narrow cisplatin dose range (Figure 3C).
F I G U R E  1  LINC00857 expression in MIBC. Association of LINC00857 expression with response to (A) gemcitabine/cisplatin (Gem/Cis; 
responders, n = 4; nonresponders, n = 7) and platinum- based chemotherapy (responders, n = 7; nonresponders n = 10). B, LINC00857 expression 
in normal urothelium (n = 16) and MIBC (n = 122). Expression data were analyzed using unpaired t test (*P < .05; line represent the median; 
the whiskers represent 10th and 90th percentile). Kaplan- Meier analysis showing correlation between LINC00857 expression levels with (C) 
recurrence- free and (D) overall survival in MIBC MiTranscriptome cohort. The high and low LINC00857 expression groups were determined based 
on the 75th and 25th percentiles. The survival curves were analyzed using the log- rank test
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3.4 | LINC00857 regulates expression of 
genes involved in chemoresistance
To further evaluate how LINC00857 contributes to 
platinum- based chemotherapy response in bladder cancer, 
we evaluated the expression levels of LINC00857 target 
genes that were identified in lung cancer.20 In MIBC, the 
expression of DIAPH3, EMR2, MMP1, STX12, and UHMK1 
was found to be significantly associated with response to 
Gem/Cis (Figure 4A) and other platinum- based chemo-
therapy (Figure 4B). PPP2R5E expression was signifi-
cantly upregulated in the non-responders to platinum- based 
chemotherapy (Figure 4B). Additionally, the expression of 
HLA-E, LMAN1, and TP53BP2 correlated significantly 
F I G U R E  2  Knockdown of 
LINC00857 expression in T24 and UM- 
UC- 3 bladder cancer cell lines. A, The 
LINC00857 expression levels 48 hours after 
siRNA- mediated knockdown. The effect of 
LINC00857 knockdown on (B) cell viability, 
(C) induction of apoptosis analyzed by 
caspase 3/7 activity, and (D) number of 
colonies formed in a colony- forming assay 
(evaluated 2 weeks after transfection). All 
data are compared to negative control (NC1) 
siRNA- transfected cells. All bars represent 
the mean ± SD (t test, *P < .05; **P < .01; 
***P < .001)
F I G U R E  3  Effect of LINC00857 on 
cisplatin sensitivity. A, The LINC00857 
knockdown efficiency in T24 and UM- 
UC- 3 cells was determined by RT- PCR 
analysis, 48 h after transfection. Gene 
expression levels were normalized against 
GAPDH housekeeping gene expression 
levels and then compared to negative 
control (NC1) siRNA- transfected cells. 
Cisplatin sensitivity of (B) T24 and (C) 
UM- UC- 3 cells 48 h after siRNA- mediated 
knockdown of LINC00857. Cell viability 
was normalized to non- cisplatin- treated 
cells. Bars and graphs represent mean ± SD 
(t test, *P < .05; **P < .01; ***P < .001)
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with response to Gem/Cis chemotherapy (Figure 4B). High 
expression of DIAPH3, LMAN1, PPP2R5E, and UHMK1 
and low HLA-E expression were significantly associated 
with shorter recurrence- free survival (P = .002, P = .006, 
P = .008, P = .002, and P = .009 resp.; Figure 4C- G). 
Moreover, high DIAPH3, HLA-E, and LMAN1 expression 
was significantly associated with shorter overall survival 
(P = .043, P = 0.018, and P = .014, resp.; Figure S2), and 
high PPP2R5E and UHMK1 expression showed a trend 
toward association with shorter overall survival in MIBC 
(P = .052 and P = .078, resp.; Figure S2).
We further evaluated the expression of DIAPH3, LMAN1, 
PPP2R5E, and UHMK1 in bladder cancer cell lines upon 
LINC00857 knockdown. The expression levels of LMAN1 
and PPP2R5E were found to be significantly downregulated 
when LINC00857 expression was reduced in T24 and in 
UM- UC- 3 cells (P < .01 and P < .001, resp.; Figure 5A,B). 
Knockdown of LMAN1, but not PPP2R5E, also sensitized 
UM- UC- 3 cells to cisplatin to a similar degree as with 
LINC00857 knockdown (Figure 5C). Gene knockdown was 
confirmed by semiquantitative RT- PCR (Figure 5D).
4 |  DISCUSSION
Muscle- invasive bladder cancer is a life- threatening disease 
as half of the diagnosed patients show progression after ini-
tial treatment, develop metastasis, and died of the disease. 
The use of platinum- based chemotherapy (either in the neo-
adjuvant setting or for metastatic patients) has been shown 
to significantly improve overall survival of the responding 
patients.3,4 However, until now, no prognostic and predictive 
biomarkers, which allow for the selection of patients who will 
benefit from chemotherapy or monitoring of the efficacy of 
the treatment, are used in the clinical management of MIBC.4 
Therefore, there is a need for new biomarkers as well as 
F I G U R E  4  Expression of LINC00857 target genes in MIBC. Association of LINC00857 target gene expression with response to (A) 
gemcitabine/cisplatin (Gem/Cis; responders, n = 29; nonresponders, n = 12) and (B) platinum- based chemotherapy (responders, n = 40; 
nonresponders n = 20). Kaplan- Meier analysis showing correlation between recurrence- free survival and (C) DIAPH3, (D) HLA-E, (E) LMAN1, 
(F) PPP2R5E, and (G) UHMK1 expression levels in the MIBC cohort of TCGA. The high and low LINC00857 expression groups were determined 
based on the 75th and 25th percentiles. The survival curves were analyzed using the log- rank test
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therapeutic targets in MIBC. Here, we analyzed the expres-
sion of lncRNAs that may be associated with the response 
to platinum- based chemotherapy using MiTranscriptome 
lncRNA expression data in patients with MIBC.
In our study, high LINC00857 expression was found to be 
associated with the lack of response to platinum- based che-
motherapy. Previously, LINC00857 was identified as one of 
the most upregulated lncRNAs in lung cancer. LINC00857 
knockdown has been shown to reduce cell viability, migra-
tion, and invasion in vitro and in vivo by regulating a vari-
ety of genes involved in cell cycle progression. Furthermore, 
similarly to what we have found in bladder cancer, high 
LINC00857 expression was associated with shorter overall 
survival of patients with lung cancer suggesting its oncogenic 
role in cancer.20
Recently, a panel of 5 lncRNAs including LINC00857 
was shown to accurately detect the presence of gastric can-
cer in blood. The high expression levels of these lncRNAs 
were also found to be correlated with tumor aggressiveness 
and lymphatic metastasis,21 an association we also found for 
LINC00857 in MIBC. Moreover, lncRNA expression levels 
decreased postoperatively, suggesting a potential to monitor 
therapy efficacy.21 A liquid biopsy has been shown to facili-
tate evaluation of a variety of potential biomarkers including 
cell- free DNA, CTCs, cell- free proteins, peptides, exosomes, 
and circulating RNAs (mRNAs, microRNAs, and lncRNAs) 
and is currently being investigated in urological malignan-
cies as well.22 The expression levels of 3 lncRNAs: MEG3, 
SNHG16, and MALAT1 were recently shown to accurately 
detect bladder cancer in serum.23 Therefore, the usefulness 
of LINC00857 and other prognostic lncRNAs as a noninva-
sive, blood- based biomarker should be evaluated in blood 
collected from patients with MIBC.
In our study, LINC00857 expression in the primary tumor 
was shown to predict MIBC progression and response to che-
motherapy. The accurate selection of patients that will not 
respond to chemotherapy could lead to earlier selection of 
other treatment regimens, leading to improved overall sur-
vival of the chemotherapy nonresponding patients. Recently, 
atezolizumab (anti- PDL1 antibody) and other checkpoint in-
hibitors were approved for the treatment of patients with ad-
vanced bladder cancer, who progressed after platinum- based 
F I G U R E  5  LINC00857 target gene expression and cisplatin sensitization in T24 and UM- UC- 3 bladder cancer cells. Expression of 
LINC00857 target genes DIAPH3, LMAN1, PPP2R5E, and UHMK1 in (A) T24 and (B) UM- UC- 3 bladder cancer cell lines upon LINC00857 
knockdown. All data are compared to NC1- siRNA- transfected cells. C, Cisplatin sensitivity of UM- UC- 3 cells 48 h after siRNA- mediated 
knockdown of LMAN1 and PPP2R5E. Cell viability was normalized to non- cisplatin- treated cells. D, The efficiency of gene knockdown in siRNA- 
transfected UM- UC- 3 cells. Gene expression levels were normalized against GAPDH housekeeping gene expression levels and then compared to 
negative control (NC1) siRNA- transfected cells. Bars and graphs represent the mean ± SD (t test, *P < .05; **P < .01; ***P < .001)
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chemotherapy, and numerous clinical trials evaluating their 
clinical effectiveness are ongoing.24
Several methods have been developed to target lncRNA 
expression, including antisense oligonucleotides, siRNAs, 
and (deoxy)ribozymes, representing a possibility of thera-
peutic intervention.25 For example, targeting SAMMSON (a 
lncRNA upregulated in melanoma) in vivo by intravenous 
treatment with antisense oligonucleotides has been shown to 
significantly suppress tumor growth in patient- derived xeno-
graft models.26 LINC00857 expression levels were found to 
be upregulated in the nonresponders group in MIBC, there-
fore targeting LINC00857 could potentially sensitize bladder 
cancer cells to chemotherapy.
Multiple LINC00857 target genes were identified in 
the lung cancer study.20 In our study, expression levels of 
DIAPH3, EMR2, MMP1, PPP2R5E, STX12, and UHMK1 
were shown to be associated with platinum- based chemo-
therapy response. Moreover, high expression of DIAPH3, 
LMAN1, PPP2R5E, and UHMK1 was correlated with 
shorter progression- free and/or overall survival. Knockdown 
of LINC00857 in bladder cancer cell lines resulted in de-
creased expression of LMAN1 and PPP2R5E, and loss of 
LMAN1 expression sensitized cells to cisplatin to a similar 
degree as knockdown of LINC00857. LMAN1 (a mannose- 
specific lectin) is responsible for transport of glycosylated 
proteins from endoplasmic reticulum to Golgi.27 It was 
shown to be frequently mutated in microsatellite instability- 
positive gastric28 and colorectal cancer.27 Moreover, lack of 
LMAN1 expression influenced transport of antiangiogenic 
and growth inhibiting protein- A1AT, contributing to col-
orectal carcinogenesis.27 PPP2R5E, a regulatory subunit of 
protein phosphatase 2A (PP2A) was found to be downregu-
lated in colorectal cancer29 and leukemia.30 Suppression of 
PPP2R5E sensitizes tumor cells to DNA damaging agents 
through regulation of cell cycle and DNA repair pathways.31 
PPP2R5E has also been found to have anti- and proapop-
totic properties and to be a substrate for caspase- 3 during 
cisplatin- induced apoptosis.32 As LINC00857 was found 
to be enriched in the cytoplasmic fraction,20 it is likely 
that LINC00857 regulates the expression of LMAN1 and 
PPP2R5E and other target genes by affecting mRNA sta-
bility or promoting its translation leading to resistance to 
platinum- induced apoptosis.
One of the limitations of our study is studying a single 
lncRNA as potential prognostic and predictive biomarker in 
MIBC. Large- scale initiatives, like the TCGA consortium, 
have identified several MIBC subtypes characterized by dis-
tinct genetic and transcriptional alterations and thus clinical 
outcomes. The lncRNAs expression was shown to be con-
cordant with the mRNA- defined subtypes but also further 
discriminated subgroups associated with survival.33,34 This 
shows that MIBC is highly a heterogeneous disease; there-
fore, likely a combination of multiple markers predicting 
progression and/or therapy response is needed to accurately 
stratify patients. We showed that LINC00857 expression is 
associated with response to platinum- based chemotherapy; 
however, the number of used patients is low. The studies on 
lncRNAs expression as potential predictive biomarkers for 
platinum- based chemotherapy in MIBC are still limited and 
focused on protein- coding genes. Moreover, MIBC patients’ 
cohorts with comprehensive lncRNAs sequencing and clini-
cal data are lacking. More studies in larger platinum- treated 
patient cohorts are needed to validate LINC00857 and other 
lncRNAs as markers of chemotherapy response in bladder 
and other cancer types (also in a neoadjuvant setting).
In conclusion, our data indicate that lncRNAs play an import-
ant role in MIBC progression and response to platinum- based 
chemotherapy. Further studies should focus on how LINC00857 
and other lncRNAs regulate pathways underlying MIBC ag-
gressiveness and chemotherapy resistance. This may ultimately 
lead to the development of new prognostic and predictive bio-
markers and possibly new treatment options for MIBC.
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